Alessandro Casini1, Marc Blondon1, Veronique Tintillier2, Matthew Goodyer3, Melike E Sezgin4, Adalet M Gunes4, Michel Hanss5, Philippe de Moerloose6, Marguerite Neerman-Arbez7. 1. Division of Angiology and Haemostasis, Faculty of Medicine, University Hospitals of Geneva, University of Geneva, Geneva, Switzerland. 2. Institut Hématologie Transfusion, Pôle Biologie Pathologie Génétique, CHRU, Lille, France. 3. Department of Haematology, Institut Central des Hôpitaux, Sion, Switzerland. 4. Department of Pediatric Hematology and Oncology, Uludag University, Bursa, Turkey. 5. Laboratoire d'Hématologie, Hospices Civils de Lyon, CBPE, Lyon, France. 6. Faculty of Medicine, University Hospitals of Geneva, University of Geneva, Geneva, Switzerland. 7. Department of Genetic Medicine and Development, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Abstract
BACKGROUND: Numerous mutations in FGA, FGB or FGG lead to congenital fibrinogen disorders (CFDs), but their epidemiology is not well characterized. The aim of this study was to evaluate the molecular epidemiology of CFD and to develop a genotyping strategy. METHODS: Genetic data from 266 unrelated CFD patients genotyped at our laboratory and from a CFD open access database (n = 1,142) were evaluated. We developed a step-wise screening strategy for the molecular diagnosis of CFD and prospectively tested this strategy on 32 consecutive CFD probands. RESULTS: We identified 345 mutated alleles overall, among 187 heterozygous, 63 homozygous and 16 compound heterozygous individuals. Afibrinogenemia was almost always caused by null mutations (98.6%), mainly in FGA (85%). Hypofibrinogenemia was mainly caused by missense mutations of FGB or FGG (54.2%). Dysfibrinogenemia was almost always caused by heterozygous missense mutations (99.3%) in FGA and FGG. Hotspot mutations were prevalent among quantitative (33.1%) and qualitative fibrinogen disorders (71.1%). The mutational cluster at our laboratory was similar with that reported in the CFD open access database. The proposed step-wise genetic screening strategy proved efficient in both the development and validation samples for CFD: the screening of FGA exons 2, 4, 5 and FGG exon 8 and search for the 11 kb deletion of FGA led to the identification of approximately 80% of mutated alleles, including 15 new mutations. CONCLUSION: The described molecular epidemiology of CFD is complex. The proposed step-wise genetic screening strategy may provide an efficient way to identify causative mutations analysing a minimal number of exons. Georg Thieme Verlag KG Stuttgart · New York.
BACKGROUND: Numerous mutations in FGA, FGB or FGG lead to congenital fibrinogen disorders (CFDs), but their epidemiology is not well characterized. The aim of this study was to evaluate the molecular epidemiology of CFD and to develop a genotyping strategy. METHODS: Genetic data from 266 unrelated CFDpatients genotyped at our laboratory and from a CFD open access database (n = 1,142) were evaluated. We developed a step-wise screening strategy for the molecular diagnosis of CFD and prospectively tested this strategy on 32 consecutive CFD probands. RESULTS: We identified 345 mutated alleles overall, among 187 heterozygous, 63 homozygous and 16 compound heterozygous individuals. Afibrinogenemia was almost always caused by null mutations (98.6%), mainly in FGA (85%). Hypofibrinogenemia was mainly caused by missense mutations of FGB or FGG (54.2%). Dysfibrinogenemia was almost always caused by heterozygous missense mutations (99.3%) in FGA and FGG. Hotspot mutations were prevalent among quantitative (33.1%) and qualitative fibrinogen disorders (71.1%). The mutational cluster at our laboratory was similar with that reported in the CFD open access database. The proposed step-wise genetic screening strategy proved efficient in both the development and validation samples for CFD: the screening of FGA exons 2, 4, 5 and FGG exon 8 and search for the 11 kb deletion of FGA led to the identification of approximately 80% of mutated alleles, including 15 new mutations. CONCLUSION: The described molecular epidemiology of CFD is complex. The proposed step-wise genetic screening strategy may provide an efficient way to identify causative mutations analysing a minimal number of exons. Georg Thieme Verlag KG Stuttgart · New York.
Authors: Tomas Simurda; Monika Brunclikova; Rosanna Asselta; Sonia Caccia; Jana Zolkova; Zuzana Kolkova; Dusan Loderer; Ingrid Skornova; Jan Hudecek; Zora Lasabova; Jan Stasko; Peter Kubisz Journal: Int J Mol Sci Date: 2020-06-29 Impact factor: 5.923
Authors: Weijie Zhou; Yan Huang; Jie Wei; Jun Li Wang; Boming Huang; Xiaoxuan Zhou; Jie Yan; Yangyang Wu; Faquan Lin; Wangrong Wen Journal: Ann Transl Med Date: 2021-08
Authors: Brenton J Francisco; Bal Krishan Sharma; Hannah M Russell; Leah Rosenfeldt; A Phillip Owens; Matthew J Flick; Eric S Mullins; Joseph Palumbo Journal: Blood Adv Date: 2022-07-26